NSTE-ACS: Risk Stratification, Antithrombotic Therapy, and Invasive Strategy

NSTE-ACS: Risk Stratification, Antithrombotic Therapy, and Invasive Strategy

A bedside framework for unstable angina and NSTEMI — high-sensitivity troponin pathways, GRACE/HEART triage, dual antiplatelet selection, and timing of coronary angiography.

Executive Summary

Non-ST-elevation acute coronary syndromes (NSTE-ACS) — encompassing unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) — represent the dominant ACS phenotype in modern catheterization-era cardiology, accounting for over two-thirds of ACS hospitalizations. The clinical task is no longer pure diagnosis (high-sensitivity cardiac troponin assays now resolve most diagnostic ambiguity within 1–3 hours) but rather risk-tiered triage: identifying which patients need immediate (within 2 hours) catheterization for hemodynamic instability, ongoing ischemia, or life-threatening arrhythmia, versus early invasive (within 24 hours) for high GRACE-risk NSTEMI, versus selective invasive for low-risk presentations. Concurrent antithrombotic therapy — aspirin plus a P2Y12 inhibitor (ticagrelor or prasugrel preferred over clopidogrel) plus parenteral anticoagulation (fondaparinux, enoxaparin, or unfractionated heparin) — must be initiated promptly while balancing bleeding risk via the CRUSADE or PRECISE-DAPT scores. This guideline operationalizes the 2020 ESC and 2025 ACC/AHA NSTE-ACS frameworks, translating algorithmic recommendations into a bedside workflow for the emergency physician, hospitalist, and cardiology consultant.
~70%
of ACS = NSTE-ACS
<1h
hs-cTn rule-out window
<24h
early invasive (high risk)
<2h
immediate cath (very high risk)

S1. Definition, Pathophysiology, and Etiology

NSTE-ACS is a clinical syndrome defined by ischemic chest discomfort or anginal-equivalent symptoms (dyspnea, jaw/arm pain, diaphoresis, syncope) without persistent ST-segment elevation on the 12-lead ECG. It is subdivided by cardiac biomarker status: NSTEMI when high-sensitivity cardiac troponin (hs-cTn) rises above the 99th-percentile upper reference limit (URL) with a dynamic change pattern, and unstable angina (UA) when ischemic symptoms occur without troponin rise. With the widespread adoption of hs-cTn assays since 2010, the UA category has shrunk dramatically — many cases formerly labeled UA now reclassify as small NSTEMIs once subclinical necrosis is detectable in the picogram range.

Underlying pathophysiology

Type 1 MI — the dominant NSTE-ACS mechanism — arises from acute atherothrombosis: rupture or erosion of a vulnerable lipid-rich plaque in an epicardial coronary artery exposes thrombogenic subendothelial collagen and tissue factor, triggering platelet adhesion (via GP Ib-vWF), activation (via thromboxane A2 and ADP), and aggregation (via GP IIb/IIIa cross-linking). Unlike STEMI, the resulting thrombus in NSTE-ACS is typically non-occlusive or subtotally occlusive, or there is brisk distal collateral flow, so transmural infarction is averted. Plaque erosion (more common in younger women) versus rupture (more common in men with high lipid burden) carries different antithrombotic implications — emerging evidence suggests erosion may be managed with antithrombotic therapy alone in selected cases (EROSION trial).

Type 2 MI — supply-demand mismatch from a non-thrombotic trigger (severe hypertension, tachyarrhythmia, hypoxemia, anemia, hypotension, severe aortic stenosis) superimposed on stable coronary disease — accounts for 25-40% of troponin-elevation hospitalizations and demands a fundamentally different management strategy: treat the precipitant, not the plaque. Distinguishing Type 1 from Type 2 is therefore the single most consequential bedside cognitive task in the NSTE-ACS workup.

EtiologyMechanismFrequencyManagement Pivot
Type 1 MI (plaque rupture)Acute atherothrombosis50-60%DAPT + anticoag + invasive
Type 1 MI (plaque erosion)Endothelial denudation, mural thrombus10-15%DAPT + anticoag (selective invasive)
Type 2 MI (supply-demand)Tachy/hypoxia/HTN/anemia + fixed CAD25-40%Treat precipitant; cath only if recurrent
Coronary spasm (vasospastic angina)Endothelial dysfunction, smooth muscle hyperreactivity2-5%CCB + nitrate; avoid beta-blocker monotherapy
Spontaneous coronary artery dissection (SCAD)Intramural hematoma, false lumen1-4% (up to 25% in young women)Conservative; PCI only if ongoing ischemia
Microvascular angina (MINOCA subtype)Coronary microvascular dysfunction5-10%Anti-anginal therapy; functional testing

S2. Diagnosis: ECG, Troponin Algorithms, and Differential

Initial ECG (within 10 minutes of presentation)

The 12-lead ECG must be obtained and interpreted within 10 minutes of first medical contact. Diagnostic features supporting NSTE-ACS include new horizontal or downsloping ST-depression ≥0.5 mm in two contiguous leads, transient ST-elevation (<20 minutes), or new T-wave inversions ≥1 mm. Critically, a normal ECG does not exclude NSTE-ACS — up to 30% of confirmed NSTEMIs have a non-diagnostic initial ECG, mandating serial tracings (every 15-30 minutes) during the diagnostic window. ST-elevation in lead aVR with diffuse ST-depression suggests left main or three-vessel disease — a true cardiology emergency warranting immediate cath.

0/1h high-sensitivity troponin algorithm Decision tree for hs-cTn rule-in and rule-out at 0 and 1 hour Chest pain + 12-lead ECG Draw hs-cTn at 0h Rule-out (0h) hs-cTn < LoD & sx >3h Observe: repeat at 1h Δ < cutoff = rule-out Rule-in hs-cTn very high or Δ↑ Discharge / OP work-up 3h hs-cTn + admit obs Admit + risk-stratify + cath
0/1h hs-cTn algorithm (ESC 2020) — rule-out, observe, or rule-in at 1 hour using assay-specific Δ cutoffs

High-sensitivity troponin protocols

Modern hs-cTn assays detect troponin in the picogram-per-liter range, allowing accelerated 0/1h or 0/2h algorithms (vs the legacy 0/3h or 0/6h pathway). The 0/1h ESC algorithm uses three assay-specific cutoffs: a rule-out threshold (very low absolute value at 0h plus minimal Δ at 1h), an observe zone (mid-range values requiring further serial testing or imaging), and a rule-in threshold (very high baseline or significant 1h Δ). Practical caveat: hs-cTn rises in many non-ACS conditions — chronic kidney disease, sepsis, heart failure, pulmonary embolism, myocarditis — so the dynamic Δ pattern (rise and fall over serial measurements) is more specific for acute MI than any single absolute value. A flat elevated troponin in a CKD patient typically represents chronic baseline myocardial injury, not acute infarction.

HEART and GRACE risk scores

Two scoring systems dominate ED triage: the HEART score (History, ECG, Age, Risk factors, Troponin; range 0-10) and the GRACE 2.0 calculator (8 variables yielding 6-month mortality estimate). HEART 0-3 identifies a low-risk cohort with <2% 6-week MACE rate, suitable for early discharge with outpatient follow-up. HEART 4-6 is intermediate (12-17% MACE) — admit for observation and stress testing or invasive evaluation. HEART ≥7 is high-risk (50-65% MACE), mandating early invasive strategy. GRACE >140 (or troponin elevation, dynamic ST changes, hemodynamic instability, ongoing pain, recent PCI/CABG, or LVEF <40%) defines the cohort that benefits from invasive cath within 24 hours.

Risk TierCriteria (any 1+)Cath TimingDisposition
Very high riskHemodynamic instability, cardiogenic shock, refractory pain, life-threatening arrhythmia, mechanical complication, acute HF<2 hours (immediate)CCU; emergent cath
High riskConfirmed NSTEMI by hs-cTn rise/fall, dynamic ST/T changes, GRACE >140<24 hours (early invasive)CCU/telemetry
Intermediate riskDiabetes, eGFR <60, LVEF <40%, prior PCI/CABG, GRACE 109-140<72 hoursTelemetry
Low riskNone of the above; HEART 0-3Selective (stress test first)Observation or discharge

S3. Antithrombotic Therapy: DAPT, Anticoagulation, GP IIb/IIIa

Aspirin loading (universal)

All NSTE-ACS patients without contraindication receive aspirin 162-325 mg PO chewed immediately at first medical contact, followed by 81-100 mg PO daily indefinitely. Chewable or non-enteric-coated formulation is preferred for rapid platelet COX-1 inhibition.

P2Y12 inhibitor (universal — agent choice depends on strategy)

The P2Y12 inhibitor selection is one of the highest-impact decisions:

  • Ticagrelor 180 mg PO load → 90 mg BID — preferred for most NSTE-ACS regardless of strategy (PLATO trial: 16% reduction in cardiovascular death vs clopidogrel). Reversible binding (offset 3-5 days). Side effects: dyspnea (~14%), bradyarrhythmias, hyperuricemia.
  • Prasugrel 60 mg PO load → 10 mg daily (5 mg if ≥75y or <60 kg) — preferred when invasive strategy is planned and coronary anatomy is known (TRITON-TIMI 38: 19% MACE reduction vs clopidogrel). Contraindicated in prior stroke/TIA; avoid in patients ≥75y unless DM or prior MI; avoid in patients <60 kg without dose reduction.
  • Clopidogrel 300-600 mg PO load → 75 mg daily — reserve for: contraindications to ticagrelor/prasugrel, concurrent oral anticoagulation (triple therapy), or high bleeding risk. Variable response due to CYP2C19 polymorphisms (loss-of-function alleles in ~30% of East Asians yield reduced platelet inhibition).

Pre-treatment timing controversy

The 2020 ESC guidelines do not recommend routine P2Y12 pre-treatment in NSTE-ACS patients planned for early invasive strategy when coronary anatomy is unknown — based on the ISAR-REACT 5 and ACCOAST trials showing no benefit and increased bleeding from upstream loading. P2Y12 inhibitor is given after coronary angiography defines the lesion and the strategy (PCI vs CABG vs medical). However, in delayed cath (>24h), STEMI, or hemodynamic instability requiring immediate stenting, upstream loading remains standard.

Parenteral anticoagulation (during hospitalization)

AgentDoseStrengthsCaveats
Fondaparinux2.5 mg SC dailyLowest bleeding risk; preferred for medical managementAdd UFH if PCI (catheter thrombosis risk); avoid if eGFR <20
Enoxaparin1 mg/kg SC q12h (0.75 mg/kg if ≥75y)Predictable dosing; no monitoringReduce to q24h if eGFR 15-30; avoid <15
Unfractionated heparin (UFH)60 U/kg IV bolus (max 4000) → 12 U/kg/hr (max 1000/hr) titrate to aPTT 1.5-2.5×Reversible (protamine); preferred in renal failure or planned CABGHIT risk; aPTT monitoring required
Bivalirudin0.75 mg/kg IV bolus → 1.75 mg/kg/hr during PCILower bleeding than UFH + GP IIb/IIIaMore acute stent thrombosis vs UFH (MATRIX trial); reserve for high-bleed-risk PCI

GP IIb/IIIa inhibitors (selective use)

Glycoprotein IIb/IIIa inhibitors (eptifibatide, tirofiban, abciximab — abciximab now discontinued in many markets) are not routinely used upstream in the modern DAPT era. They remain in the toolkit for bailout during PCI for large thrombus burden, no-reflow, or peri-procedural ischemic complication. Eptifibatide 180 mcg/kg IV bolus × 2 (10 min apart) → 2 mcg/kg/min infusion for 18-24h post-PCI. Tirofiban 25 mcg/kg IV bolus → 0.15 mcg/kg/min for 18-24h. Both require renal dose adjustment.

Bleeding risk assessment

Before committing to potent DAPT, calculate the CRUSADE score (in-hospital major bleeding) or PRECISE-DAPT score (out-of-hospital bleeding 0-12 months). High bleeding risk (PRECISE-DAPT ≥25, ARC-HBR criteria) shifts the calculus toward shorter DAPT (3-6 months) followed by P2Y12 monotherapy or aspirin alone, particularly in patients on concurrent oral anticoagulation for AF or mechanical valves. The TWILIGHT, MASTER-DAPT, and STOPDAPT-2 trials support shortened DAPT followed by ticagrelor or clopidogrel monotherapy in high-bleed-risk PCI cohorts.

NSTE-ACS — Procedure Steps Surgical stepper: NSTE-ACS — Procedure Steps NSTE-ACS — Procedure Steps 1 Initial therapy ASA 162-325mg chewed; loading P2Y12 (ticagrelor 180mg OR clopidogrel 600mg); anticoagulation (hepari 2 Antianginal Nitroglycerin 0.4mg SL q5min × 3 OR IV 5-200 mcg/min; metoprolol 25-50mg PO BID; morphine 2-4mg IV P 3 Risk stratification Calculate GRACE risk score; serial troponins (high-sensitivity 0/1h or 0/3h algorithms); ECG 4 Coronary angiography timing Very high risk: <2h; high risk: <24h; intermediate: <72h; low risk: selective (depending on stress t 5 Revascularization PCI with DES for culprit; CABG if multi-vessel CAD/diabetes; complete revascularization preferred 6 Long-term DAPT × 12 mo (ASA 81mg + ticagrelor 90mg BID OR prasugrel 10mg daily); statin (high-intensity);
NSTE-ACS — Procedure Steps

S4. Invasive Strategy: Timing and Revascularization

Cath laboratory timing matrix

Invasive strategy timing is one of the most studied questions in modern NSTE-ACS care. The TIMACS, VERDICT, and EARLY trials inform the current four-tier framework:

TimingIndicationEvidence
Immediate (<2 h)Hemodynamic instability, cardiogenic shock, refractory ischemic pain, life-threatening arrhythmia (VT/VF), mechanical complication (papillary muscle rupture, VSD), acute decompensated HFClass I — extrapolated from STEMI
Early (<24 h)Confirmed NSTEMI (hs-cTn rise/fall), dynamic ST changes, GRACE >140TIMACS subgroup: 28% MACE reduction in high-risk; VERDICT confirmed
Delayed invasive (<72 h)Diabetes, CKD eGFR 30-60, LVEF <40%, post-MI angina, prior PCI/CABG, GRACE 109-140Class IIa
Selective invasive (after stress test)Low risk: HEART 0-3, no troponin rise, normal ECG, stableOutpatient stress imaging; cath only if ischemia provoked

Revascularization choice: PCI vs CABG

Coronary anatomy from diagnostic angiography drives revascularization:

  • Single-vessel disease (non-LM): PCI to culprit lesion with drug-eluting stent (DES). DAPT minimum 12 months for DES + ACS.
  • Multivessel disease: SYNTAX score and Heart Team discussion. Low SYNTAX (≤22) — PCI acceptable. Intermediate (23-32) — individualize. High (>32) or left main with multivessel — CABG preferred.
  • Left main disease: CABG remains gold standard; PCI acceptable for low SYNTAX (EXCEL, NOBLE trials — controversial in long-term mortality).
  • Diabetes + multivessel: CABG preferred (FREEDOM trial — significant survival advantage of CABG over PCI at 5 years).

Adjunctive medical therapy

Beta-blockers metoprolol 25-50 mg PO BID within 24 hours unless contraindicated (acute HF, hypotension, bradycardia, AV block, active asthma, cocaine use). High-intensity statin atorvastatin 40-80 mg PO daily or rosuvastatin 20-40 mg PO daily regardless of baseline LDL. ACE inhibitor lisinopril 5-40 mg PO daily or ARB if intolerant; especially in LVEF <40%, anterior MI, hypertension, diabetes, or CKD. Aldosterone antagonist eplerenone 25-50 mg PO daily if LVEF ≤40% with HF symptoms or diabetes (EPHESUS trial).

S5. Special Populations and Discharge Planning

When to involve interventional cardiology immediately

(1) Hemodynamic instability or cardiogenic shock; (2) refractory ischemic chest pain despite maximal medical therapy; (3) life-threatening ventricular arrhythmia; (4) new mechanical complication (acute MR, VSD, free wall rupture); (5) recurrent dynamic ST changes; (6) failed thrombolysis (rare in NSTE-ACS but applicable when STEMI was initially suspected); (7) cardiac arrest with successful ROSC and ECG features suggesting ongoing ischemia.

Elderly (≥75 years)

Older patients derive equal or greater absolute benefit from invasive strategy (After Eighty trial: invasive vs conservative reduced MACE by 47% in NSTEMI ≥80y) but carry higher bleeding and procedural risk. Adjustments: prasugrel reduced to 5 mg daily; consider clopidogrel if prasugrel/ticagrelor not tolerated; reduce enoxaparin to 0.75 mg/kg q12h; reduce contrast volume; pre-procedure hydration for AKI prevention. Frailty assessment (Clinical Frailty Scale ≥6) may shift toward conservative strategy in selected cases.

Chronic kidney disease

CKD patients are systematically undertreated despite paradoxically higher absolute mortality benefit from guideline-directed therapy. Key adjustments: enoxaparin contraindicated if eGFR <15 (use UFH); fondaparinux contraindicated <20; reduce IV contrast (use isosmolar agent, hydration with isotonic saline 1 mL/kg/h × 6h pre-procedure and post-procedure if dialysis-dependent skip hydration). Dialysis patients require careful timing of cath relative to dialysis sessions.

Concurrent oral anticoagulation (AF, mechanical valve, VTE)

Triple therapy (OAC + aspirin + P2Y12) carries 2-3× bleeding risk vs DAPT alone. Modern strategy (AUGUSTUS, PIONEER-AF, RE-DUAL PCI, ENTRUST-AF PCI trials): drop aspirin at hospital discharge or within 1 week, continue DOAC + clopidogrel for 6-12 months, then DOAC monotherapy. Apixaban, rivaroxaban (2.5 mg BID for AF + ACS post-PCI), edoxaban, and dabigatran all studied. Avoid ticagrelor or prasugrel in triple therapy.

Discharge ComponentSpecificsDuration
Aspirin81 mg PO dailyIndefinite
P2Y12 inhibitorTicagrelor 90 mg BID (or prasugrel 10 mg daily, or clopidogrel 75 mg daily)12 months minimum (DES + ACS); shorter if HBR
High-intensity statinAtorvastatin 80 mg or rosuvastatin 40 mg dailyIndefinite; LDL goal <55 mg/dL (ESC) or <70 (ACC/AHA)
Beta-blockerMetoprolol succinate 50-200 mg daily, carvedilol 25 mg BIDIndefinite if LVEF <40%; otherwise ≥3 years
ACEi/ARBLisinopril, ramipril, losartanIndefinite if LVEF <40%, HTN, DM, CKD
Aldosterone antagonistEplerenone 25-50 mg dailyIf LVEF ≤40% + HF or DM
Cardiac rehabilitation12-week supervised exercise + educationClass I — 25% mortality reduction
Smoking cessationCounseling + varenicline or NRTGreater MACE reduction than any drug
Influenza vaccinationAnnuallyClass I (reduces MACE)

Practice Insights: Bedside Notes on NSTE-ACS

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Troponin confirms the infarct in NSTE-ACS but says nothing about when that patient should reach the catheterization laboratory, and the consistent system change that has moved the outcomes is using the GRACE risk score in the ED note to define the invasive-strategy window, and switching morphine for fentanyl in any P2Y12-loaded patient.

hs-cTn 0/1h or 0/2h Algorithm — Rule-In and Rule-Out at the Bedside

The ESC 0/1-hour and 0/2-hour high-sensitivity troponin algorithms let experienced clinicians commit to either rule-in or rule-out within 1–2 hours of arrival in roughly 75% of patients, instead of the old 4–6-hour serial protocol. In published series, these patients with chest pain plus normal ECG plus initial hs-cTn below assay-specific rule-out threshold get the 1-hour repeat; if delta troponin is below the rule-out cutoff, rule-out is committed and outpatient evaluation booked. Patients with rising delta above rule-in threshold get committed to NSTE-ACS at hour 1 and cath plans started. The 25% who fall into the observe zone get the 3-hour repeat with cardiology consultation.

GRACE Score in the ED Note Drives Invasive Timing

The GRACE risk score (age, HR, SBP, creatinine, Killip class, ST deviation, cardiac arrest, troponin) predicts in-hospital and 6-month mortality and is the primary tool for invasive strategy timing. Routinely, experienced practice documents GRACE in the ED admission note: GRACE >140 or any very-high-risk criterion (hemodynamic instability, refractory ischemia, sustained VT, mechanical complication, recurrent dynamic ischemic ECG changes) triggers an early invasive call — <2 hours for very high risk, <24 hours for high risk. GRACE 109–140 with comorbidities (diabetes, CKD, EF <40%, prior CABG or recent PCI) gets invasive within 72 hours. GRACE <108 with no high-risk features can get a selective invasive strategy after non-invasive testing.

Skip P2Y12 Pre-Treatment in the ED

The 2020 ESC guidelines stopped recommending routine P2Y12 pre-treatment before angiography in NSTE-ACS based on the DUBIUS and ISAR-REACT 5 trials, which showed no ischemic benefit and increased bleeding risk when ticagrelor or prasugrel are given before knowing coronary anatomy. In practice seasoned clinicians load aspirin 162–325 mg at first medical contact but hold the P2Y12 inhibitor until cath confirms PCI is the plan; if CABG turns out to be the strategy, experienced clinicians have not committed the patient to a 5-day prasugrel/ticagrelor hold. ACC/AHA still allows pre-treatment, but the European evidence has changed experienced practice. The exception is true STEMI activation where pre-PCI loading remains standard.

Fentanyl, Not Morphine, in Any P2Y12-Loaded Patient

Morphine delays absorption and onset of oral P2Y12 inhibitors meaningfully — published data show ticagrelor and prasugrel peak effect is delayed by hours when morphine is co-administered, with measurable platelet reactivity persisting at the time of cath. In practice IV fentanyl 25–50 mcg titrated is the analgesic of choice in NSTE-ACS once P2Y12 has been or will be loaded; morphine is reserved for refractory pain after fentanyl, with the trade-off acknowledged. Nitroglycerin sublingual or IV remains first-line for ischemic pain control before any opioid.

Illustrative Scenario: GRACE 145 With Cath Within 18 Hours

A man in his late 60s with diabetes and prior PCI 18 months earlier presented with 4 hours of substernal chest pain. ECG showed 1 mm ST depression in V4–V6 without ST elevation; hs-cTn at 0 hours was 35 ng/L (above rule-out) and at 1 hour was 142 ng/L (clear delta above rule-in threshold). GRACE score calculated to 145 (age 68, HR 92, SBP 138, Cr 1.3, Killip I, ST depression, no arrest, elevated troponin). NSTE-ACS confirmed and high-risk category. The treating clinicians gave aspirin 325 mg, atorvastatin 80 mg, IV fentanyl 50 mcg for ongoing pain, unfractionated heparin 60 U/kg bolus + 12 U/kg/hr infusion; held the P2Y12 inhibitor pending cath. Cath at hour 18 from arrival showed a 95% in-stent restenosis in the LAD; PCI with drug-eluting stent was performed and ticagrelor 180 mg loading dose was given on the table immediately after stent deployment. He was discharged on day 4 on aspirin 81 mg, ticagrelor 90 mg BID, atorvastatin 80 mg, lisinopril 10 mg, metoprolol succinate 50 mg, with cardiac rehab referral in 3 weeks and follow-up at 4 weeks.

Takeaway: GRACE score in the ED note defines the cath window. Hold P2Y12 until anatomy is known. Use fentanyl over morphine in any acute coronary syndrome patient who has been or will be loaded on a P2Y12 inhibitor.

Protocol Adjustments Experienced Practice Uses Beyond the Standard Guideline

  • hs-cTn 0/1h or 0/2h algorithm at first contact — commits ~75% of patients to rule-in or rule-out within 2 hours. Old 4–6-hour serial protocol is obsolete with current assays.
  • GRACE score in the ED note drives invasive timing — very high risk <2 h, high risk <24 h, intermediate <72 h, low risk selective. Document the score, not "needs cath."
  • Skip P2Y12 pre-treatment; load on the cath table — ESC 2020 + DUBIUS + ISAR-REACT 5. Aspirin 162–325 mg at first contact; hold ticagrelor/prasugrel until coronary anatomy known. Exception: confirmed STEMI activation.
  • Fentanyl, not morphine, in any P2Y12-loaded patient — morphine delays oral P2Y12 onset for hours. Fentanyl 25–50 mcg IV titrated; nitroglycerin first; morphine only if refractory.
NSTE-ACS Pathway: hs-cTn → GRACE → Invasive Window → DAPT Strategy Four-step decision pathway showing rapid hs-troponin algorithm, GRACE risk stratification into four invasive timing tiers, antithrombotic loading sequence with P2Y12 hold, and discharge bundle. NSTE-ACS: GRACE Drives the Cath Window Score in the ED note, hold P2Y12 until anatomy known, fentanyl over morphine STEP 1 — hs-cTn 0/1h or 0/2h ESC algorithm → rule-in / rule-out / observe ~75% committed within 2 hours · obsolete to wait 4–6 h with current assays STEP 2 — GRACE score in ED note → invasive timing window Very high risk HD instability · refractory pain sustained VT · mech complic. Cath <2 h High risk GRACE >140 OR dynamic Tn OR new ST depression Cath <24 h Intermediate risk GRACE 109–140 DM · CKD · EF <40 · prior PCI Cath <72 h Low risk GRACE <108 No high-risk feature Selective invasive STEP 3 — Aspirin 162–325 mg load · UFH 60 U/kg bolus + 12 U/kg/hr · HOLD P2Y12 P2Y12 (ticagrelor 180 mg / prasugrel 60 mg / clopi 600 mg) loaded ON CATH TABLE after anatomy ESC 2020 + DUBIUS + ISAR-REACT 5 — no benefit, more bleeding from pre-treatment STEP 4 — Discharge bundle ASA 81 + P2Y12 12 mo · Atorva 80 / Rosuva 40 ACEi/ARB if HTN/DM/EF<40 · Beta-blocker SGLT2i if T2DM/CKD/HF · cardiac rehab in 3 wk ⛔ Pain control: fentanyl over morphine ⛔ NSAIDs contraindicated post-MI Smoking cessation pharmacotherapy

S6. Pearls, Pitfalls, and FAQ

Pearl 1 — Use Δ troponin, not absolute value

In CKD, sepsis, HF, PE, and chronic myocardial injury, baseline hs-cTn is elevated and stable. The dynamic rise-and-fall pattern over serial measurements (Δ ≥20-50% of URL) is what separates acute MI from chronic injury. A flat 80 ng/L hs-cTn in a dialysis patient with atypical chest pain rarely reflects acute infarction; the same value with a 30% rise at 1h and continuing rise at 3h almost always does.

Pitfall 1 — Treating Type 2 MI with DAPT and cath

Sepsis, hypoxemia, severe HTN, tachyarrhythmia, anemia, and shock all cause troponin elevation through supply-demand mismatch. Aggressive antiplatelet/anticoagulation in this setting harms more than helps — bleeding rises without modifying the underlying mechanism. Treat the precipitant (transfuse, control HR, oxygenate, treat sepsis) and reserve cath for recurrent ischemia after the trigger resolves.

Pearl 2 — aVR ST-elevation = left main equivalent

ST-elevation in aVR ≥1 mm with diffuse ST-depression in ≥6 leads strongly suggests left main, ostial LAD, or three-vessel disease. This is one of the highest-mortality ECG patterns in cardiology — call interventional cardiology immediately, avoid full P2Y12 loading until anatomy known (likely CABG candidate), and prepare for emergent cath.

Pitfall 2 — Pre-loading P2Y12 before knowing anatomy

ISAR-REACT 5 and ACCOAST showed upstream prasugrel/ticagrelor before angiography increased bleeding without ischemic benefit. If CABG is needed, full P2Y12 inhibition mandates 5-7 day delay (ticagrelor: 3-5 days; prasugrel: 7 days; clopidogrel: 5 days), prolonging hospitalization and increasing in-hospital event risk. Wait until anatomy is defined.

Pearl 3 — Dual pathway: rivaroxaban 2.5 mg BID + aspirin

The COMPASS trial established that low-dose rivaroxaban (2.5 mg BID) added to aspirin reduces MACE in stable atherosclerotic disease (post-MI, PAD, stable CAD) at the cost of modest bleeding. In high-ischemic-risk NSTE-ACS patients without high bleed risk, transitioning from DAPT to dual pathway after 12 months may further reduce ischemic events.

Pitfall 3 — Forgetting MINOCA work-up

5-10% of NSTEMIs have non-obstructive coronaries on cath (MINOCA: MI with non-obstructive coronary arteries). This is not "ruled out for ACS" — it requires follow-up with cardiac MRI (myocarditis, takotsubo, infarction patterns), provocation testing (vasospasm), thrombophilia screen if young, and SCAD evaluation in young women. Misclassifying MINOCA as "false positive" misses treatable underlying disease.

Frequently Asked Questions

Q1. Can NSTE-ACS be ruled out with a single hs-cTn at presentation?
Yes — but only in carefully selected patients. The ESC 0/1h algorithm permits rule-out with a single hs-cTn measurement when the value is below the assay-specific limit of detection (LoD) AND symptoms began >3 hours prior. If sx began <3h (insufficient time for troponin rise) or the value is above LoD, a 1h or 3h repeat is required. The HEART pathway (HEART 0-3 + non-elevated initial troponin + non-diagnostic ECG) similarly permits early discharge without serial troponins, with <1% 30-day MACE in derivation/validation cohorts.
Q2. Is upstream P2Y12 inhibitor loading still recommended?
Not routinely for NSTE-ACS planned for early invasive strategy. The 2020 ESC and 2025 ACC/AHA frameworks recommend deferring P2Y12 selection until coronary anatomy is defined at angiography, since pre-loading delays CABG by 5-7 days (if needed) and increases bleeding without ischemic benefit (ISAR-REACT 5, ACCOAST). Exceptions: STEMI, hemodynamic instability, delayed cath (>24h), or known coronary anatomy from prior cath where PCI is planned.
Q3. Ticagrelor vs prasugrel — which is preferred?
For NSTE-ACS with planned PCI and anatomy known, prasugrel showed superiority over ticagrelor in ISAR-REACT 5 (HR 0.71 for primary endpoint of death/MI/stroke) — but prasugrel is contraindicated in prior stroke/TIA and requires dose reduction in elderly/low body weight. For most other contexts (medical management, conservative strategy, unknown anatomy at presentation, prior stroke/TIA), ticagrelor remains preferred per PLATO. Clopidogrel is reserved for triple therapy or HBR.
Q4. How long should DAPT continue after PCI for NSTE-ACS?
Standard is 12 months DAPT (aspirin + ticagrelor/prasugrel/clopidogrel) after DES placement for ACS, followed by aspirin monotherapy indefinitely. High bleeding risk patients (PRECISE-DAPT ≥25, ARC-HBR criteria) — shorten to 3-6 months DAPT then ticagrelor or clopidogrel monotherapy (TWILIGHT, MASTER-DAPT, STOPDAPT-2 ACS). Very high ischemic risk with low bleeding risk — extend DAPT beyond 12 months or transition to dual pathway (aspirin + rivaroxaban 2.5 mg BID per COMPASS).
Q5. What is MINOCA and how is it managed?
MINOCA = Myocardial Infarction with Non-Obstructive Coronary Arteries (<50% stenosis on angiography). Affects 5-10% of NSTEMIs. Workup: cardiac MRI to identify underlying etiology (myocarditis, takotsubo, true infarction from plaque erosion or distal embolization), provocation testing for vasospasm, thrombophilia screen if young or recurrent, SCAD evaluation in young women, intracoronary imaging (OCT or IVUS) to detect plaque erosion or dissection missed on angiography. Management is etiology-specific: DAPT + statin if true plaque erosion/distal embolization; CCB + nitrate if vasospasm; supportive care if takotsubo; immunosuppression if myocarditis.

Leave a Reply

Your email address will not be published. Required fields are marked *